Rayonier Advanced Materials just posted Q1 results that beat revenue estimates — and still fell 6% on the week.
That tension sits at the heart of this note. Revenue came in at $319 million, clearing the $302.5 million consensus. Adjusted EBITDA was $8 million. Yet the stock has shed 13% over the past month, closing at $9.29 on May 5. The print itself wasn't the market's primary concern — the announcement of a formal strategic alternatives review, which the company disclosed on April 20, is now the dominating narrative. Morgan Stanley has been engaged as financial adviser. Options on the table include a sale of part or all of the company, a merger, a strategic partnership, or capital structure actions to address the company's $761 million in net debt.
The positioning data tells a cautious story on the short side. Short interest climbed roughly 22% over the past month to 5.6% of the free float — a meaningful move, but one that appears to have stalled near its recent highs. The build was concentrated in the two weeks around April 9–24, when short interest jumped from 4.6% to 5.7% in quick succession, a period that overlapped almost exactly with the strategic review announcement. Since April 27 it has slowly edged lower, down about 1.8% over the past week. Borrow remains cheap — cost to borrow is running at 0.56% annually, barely changed from a month ago — and availability is loose, meaning there is no squeeze pressure in the lending market. The borrow market is not treating this as a high-conviction short; it looks more like positioning ahead of a binary event than a structural bear thesis.
Options paint a more defensive picture. The put/call ratio has pulled back to 1.23 from above 1.5 in mid-to-late April, suggesting some hedging demand has come off following the earnings release. That said, the current level still tracks above the 20-day mean of 1.20, and the ratio has spent the past month consistently above 1.0. Over the prior six months it hovered closer to 0.90–0.99. The shift has been gradual but clear: options participants have been running heavier put cover since the strategic review was announced.
The sole analyst on record — RBC Capital, maintaining an Outperform — last updated its target in March, raising it from $9 to $14. That $14 target represents roughly 50% upside from the current price. The company's 2025 full-year result was ugly: a net loss of $420 million against $1.47 billion in revenue, driven in part by non-cash charges. Q1 2026 showed some stabilisation — the CFO flagged a 17% year-on-year increase in average cellulose specialties sales price, and the company generated $12 million of adjusted free cash flow even in a weak quarter. The bear case centres on High Purity Cellulose volume headwinds, ongoing oversupply in Asian high-yield pulp markets, and a balance sheet where $761 million of net debt leaves little room for error. The bull case rests on USMCA-compliant product lines that benefit from current tariff dynamics, an improving CS pricing trajectory, and the possibility that the strategic review crystallises hidden asset value.
Institutional ownership has a few notable features. AIP, LLC entered a 5% stake as recently as February 2026, acquiring 3.14 million shares in what appears to have been a fresh position. BlackRock and Vanguard hold roughly 7% and 5% respectively and modestly added to their positions in Q1. Condire Investors sits at 9.4% as the largest single holder. The register does not read like one poised for near-term selling pressure — the concentration of active managers at these levels suggests some holders are positioned for the strategic review outcome rather than running for the exits.
The key question now is not about the next quarterly print — there isn't one scheduled yet. It is whether the strategic review produces a concrete outcome. Management gave no timeline on the call. With $160 million of liquidity (including revolver availability) and a debt load that weighs on every capital allocation decision, the range of potential outcomes — from debt restructuring to an outright sale — is wide enough to keep the risk profile elevated regardless of near-term operational progress.
See the live data behind this article on ORTEX.
Open RYAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
